Links between nocturnal hypoxia and cognitive function in breast cancer

Clara Elia(Inserm), Bénédicte Giffard(Inserm), Florence Joly(Centre François Baclesse), Jean‐Michel Grellard(Centre François Baclesse), Francis Eustache(Inserm), Mylène Duivon(Inserm), Carine Segura‐Djezzar(Centre François Baclesse), Patrice Clochon(Inserm), Djelila Allouache(Centre François Baclesse), Christelle Lévy(Centre François Baclesse), George Emile(Centre François Baclesse), Julien Geffrelot(Normandie Université), Joy Perrier(Inserm), François Christy(Inserm), Fausto Viader(Inserm), Marie Fernette(Centre François Baclesse), Stéphane Rehel(Inserm), Franck Doidy(Inserm), François Gernier(Inserm)

Research Square

October 29, 2025

10.21203/rs.3.rs-6016528/v1

Cited by 0

Related Papers

ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

|Annals of Oncology|2019|1.2k

ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

|Annals of Oncology|2024|277

Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses

|European Urology|2020|246

Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial

|The Lancet Oncology|2021|148

Proton therapy for locally advanced breast cancer: A systematic review of the literature

|Cancer Treatment Reviews|2017|60